ARTICLE | Company News
Targeted Genetics other research news
October 14, 1996 7:00 AM UTC
TGEN received a $100,000 Phase I SBIR from the National Cancer Institute to support its Phase I trial of the HER-2/neu inhibitor for breast and ovarian cancers that overexpress the HER-2/neu oncogene....